During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

"Congratulations!" "Er, thanks — what for?" "For beating cancer!" Congratulations are certainly due but not to me. I was just ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

Researchers sought to determine whether CNS bridging radiotherapy would improve responses to CAR-T therapy in patients with B-cell lymphomas.

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their ...